Cytokinetics, Incorporated
CYTK
$32.15
-$0.33-1.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.22M | 18.47M | 3.22M | 3.13M | 3.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.22M | 18.47M | 3.22M | 3.13M | 3.75M |
| Cost of Revenue | 357.68M | 339.41M | 330.76M | 328.68M | 332.27M |
| Gross Profit | -338.46M | -320.93M | -327.54M | -325.54M | -328.52M |
| SG&A Expenses | 227.18M | 215.31M | 197.09M | 180.55M | 169.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 584.86M | 554.72M | 527.85M | 509.22M | 501.72M |
| Operating Income | -565.64M | -536.25M | -524.63M | -506.09M | -497.97M |
| Income Before Tax | -615.26M | -589.53M | -576.40M | -545.28M | -530.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -615.26 | -589.53 | -576.40 | -545.28 | -530.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -615.26M | -589.53M | -576.40M | -545.28M | -530.60M |
| EBIT | -565.64M | -536.25M | -524.63M | -506.09M | -497.97M |
| EBITDA | -556.14M | -526.72M | -511.14M | -493.16M | -485.59M |
| EPS Basic | -5.31 | -5.28 | -5.39 | -5.37 | -5.40 |
| Normalized Basic EPS | -3.32 | -3.30 | -3.37 | -3.36 | -3.38 |
| EPS Diluted | -5.31 | -5.28 | -5.39 | -5.37 | -5.40 |
| Normalized Diluted EPS | -3.32 | -3.30 | -3.37 | -3.36 | -3.38 |
| Average Basic Shares Outstanding | 463.50M | 446.92M | 427.92M | 406.30M | 392.82M |
| Average Diluted Shares Outstanding | 463.50M | 446.92M | 427.92M | 406.30M | 392.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |